Test identifies breast cancer patients with lowest risk of death

A molecular test can pinpoint which patients will have a very low risk of death from breast cancer even 20 years after diagnosis and tumor removal, according to a new clinical study led by UC San Francisco in collaboration with colleagues in Sweden. As a result, "ultralow" risk patients could be treated less aggressively and overtreatment avoided, leading to fewer toxic effects.